Tempus AI Executives Sell Shares Amid Strategic Acquisitions and FDA Clearance

Tempus AI CEO Eric Lefkofsky sells $7 million in shares By Investing.com

Eric Lefkofsky, CEO and Chairman of Tempus AI, Inc. (NASDAQ:TEM), recently sold shares worth approximately $7,045,334, according to an SEC filing. The transactions occurred on December 18, 2024, with the sale prices ranging from $37.34 to $39.38 per share. The sale comes as the stock has experienced a significant 13% decline over the past week, according to InvestingPro data. Following these transactions, Lefkofsky retains significant holdings in the company through various entities, including Blue Media, LLC and Gray Media, LLC. The sales were made under a pre-established trading plan. The $5.2 billion market cap company currently trades near its InvestingPro Fair Value, maintaining a solid liquidity position with a current ratio of 2.69 and showing strong revenue growth of 32% year-over-year. InvestingPro subscribers can access 6 additional key insights about Tempus AI's financial health and market position. In other recent news, Tempus AI has experienced significant changes in its stock price targets following its latest earnings report and strategic acquisition of genetics firm Ambry. Piper Sandler raised its price target from $40 to $70, maintaining a Neutral rating. Stifel downgraded the stock from Buy to Hold, but increased the price target to $65. Needham raised its stock price target to $56, keeping its Buy rating. Tempus AI's acquisition of Ambry Genetics is viewed as a key strategic move, potentially offering immediate genomics capabilities and future opportunities in data and applications. The company has also partnered with Avacta Therapeutics to advance oncology drug development using AI, granting Avacta access to Tempus's comprehensive multimodal datasets. Further, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These are among the recent developments surrounding Tempus AI.

Tempus AI chief accounting officer sells $13,637 in stock By Investing.com

Ryan M. Bartolucci, the Chief Accounting Officer at Tempus AI, Inc. (NASDAQ:TEM), a company currently valued at $6.1 billion, sold 339 shares of Class A Common Stock on December 16. According to InvestingPro data, the stock has experienced a 7% decline over the past week. The shares were sold at an average price of $40.23, resulting in a total transaction value of $13,637. This transaction was part of a mandatory sale to cover tax obligations related to the vesting of restricted stock units, as specified by the company's equity incentive plans. Following this transaction, Bartolucci retained ownership of 71,007 shares. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 2.69, indicating healthy short-term financial stability. Subscribers can access 8 additional key insights about TEM's financial health and market position on the platform. In other recent news, Tempus AI has been the subject of multiple analyst revisions following their recent earnings report. Piper Sandler notably increased their price target for the company from $40 to $70, maintaining a Neutral rating. This adjustment came in the wake of Tempus AI's acquisition of Ambry Genetics, a strategic move that promises significant opportunities in data and applications over time. Meanwhile, Stifel downgraded Tempus AI from Buy to Hold, but raised their price target to $65. In a similar vein, Needham raised its price target for Tempus AI to $56, while maintaining a Buy rating. This adjustment was prompted by the company's third-quarter results, which exceeded market expectations. Tempus AI's CEO, Eric Lefkofsky, has deferred the settlement of approximately 4.47 million restricted stock units to a period between January 15, 2025, and March 15, 2025. In other developments, Tempus AI has entered into a strategic collaboration with Avacta Therapeutics, aiming to utilize AI in advancing oncology drug development. Avacta will gain access to Tempus AI's comprehensive multimodal datasets, which include primary tumor samples and associated clinical data from over 200,000 patients. Finally, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These are the recent developments surrounding Tempus AI.

Tempus AI's COO Ryan Fukushima sells shares worth $140,805 By Investing.com

Ryan Fukushima, Chief Operating Officer of Tempus AI, Inc. (NASDAQ:TEM), has reported the sale of 3,500 shares of Class A Common Stock. The shares were sold at an average price of $40.23 per share, amounting to a total transaction value of approximately $140,805. The stock has since declined to $34.30, part of a broader 7.24% decline over the past week, according to InvestingPro data. This sale was conducted to cover statutory tax withholding obligations related to the vesting of restricted stock units, as mandated by Tempus AI's equity incentive plans. Following the transaction, Fukushima holds 1,003,707 shares directly. Additionally, there are 131,893 shares held indirectly by the Ryan Fukushima Irrevocable Family Trust and 150,000 shares held by his spouse. The company, currently valued at $6.13 billion, has shown strong revenue growth of 32.13% and maintains healthy liquidity with a current ratio of 2.69. Investors will note that the sale was a non-discretionary action required by company policy rather than a voluntary decision by Fukushima. InvestingPro subscribers can access additional insights, including multiple analyst revisions and detailed financial health metrics, to better understand TEM's current market position. In other recent news, Tempus AI has been the subject of several analyst adjustments following its recent earnings report. Piper Sandler notably increased its price target from $40 to $70, while maintaining a Neutral rating on the shares. The acquisition of genetics firm Ambry, however, was not factored into these estimates. Stifel also adjusted its stance on Tempus AI, downgrading the stock from Buy to Hold, but simultaneously raising its price target to $65. Needham, on the other hand, increased its stock price target to $56 and maintained a Buy rating. Tempus AI's acquisition of Ambry Genetics is seen as a strategic move, introducing immediate genomics capabilities and providing opportunities in data and applications over time. The company has also partnered with Avacta Therapeutics to utilize AI in advancing oncology drug development. This collaboration will provide Avacta access to Tempus's comprehensive multimodal datasets. In addition, Tempus AI's CEO, Eric Lefkofsky, has deferred the settlement of approximately 4.47 million restricted stock units to a period between January 15, 2025, and March 15, 2025. The company has also invested $36 million in Personalis (NASDAQ:PSNL), Inc., acquiring shares and exercising warrants for additional stock. Lastly, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These are the recent developments surrounding Tempus AI.

Tempus AI EVP Andrew Polovin sells shares worth $45,459 By Investing.com

Andrew Polovin, Executive Vice President and General Counsel at Tempus AI, Inc. (NASDAQ:TEM), recently sold 1,130 shares of the company's Class A common stock. The stock has seen significant volatility, dropping 7% in the past week while maintaining a 28% gain over the last six months. The transaction, dated December 16, 2024, amounted to $45,459, with shares sold at a weighted average price of $40.23. According to the filing, this sale was conducted to cover statutory tax withholding obligations related to the vesting of restricted stock units, as mandated by Tempus AI's equity incentive plans. Following this transaction, Polovin retains ownership of 244,955 shares in the company, which represents a stake in Tempus AI's $6.1 billion market capitalization. The company maintains strong liquidity with a current ratio of 2.69, indicating healthy short-term financial positioning. InvestingPro subscribers can access 8 additional key insights about Tempus AI's financial health and market position. In other recent news, Tempus AI has been the focus of several financial firms following its recent earnings report and acquisition of genetics firm, Ambry. Piper Sandler increased Tempus AI's price target from $40 to $70, maintaining a neutral rating. Stifel downgraded Tempus AI from Buy to Hold, but increased its price target to $65. Needham raised its price target to $56 and maintained a Buy rating. These adjustments came on the heels of Tempus AI's third-quarter results, which exceeded market expectations, and the strategic acquisition of Ambry Genetics. The acquisition is expected to introduce immediate genomics capabilities and significant opportunities in data and applications over time. Tempus AI has also partnered with Avacta Therapeutics to utilize AI in advancing oncology drug development, providing Avacta access to Tempus's comprehensive multimodal datasets. Furthermore, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These are the recent developments surrounding Tempus AI.

Tempus AI EVP Erik Phelps sells $96,391 in stock By Investing.com

CHICAGO -- Erik Phelps, Executive Vice President and Chief Administrative and Legal Officer at Tempus AI, Inc. (NASDAQ:TEM), recently sold 2,396 shares of the company's Class A Common Stock. The transaction, which took place on December 16, was valued at approximately $96,391, with a weighted average sale price of $40.23 per share. Since then, TEM shares have declined significantly, currently trading at $34.30, reflecting broader market pressure that has seen the stock drop over 7% in the past week. According to the filing, the sale was not discretionary. It was conducted to cover statutory tax withholding obligations related to the vesting of restricted stock units, a process mandated by Tempus AI's equity incentive plans. Following this transaction, Phelps retains ownership of 220,596 shares in the company, representing a stake in the $6.13 billion market cap company. InvestingPro data shows the company maintains healthy liquidity with a current ratio of 2.69, while achieving strong revenue growth of 32% in the last twelve months. The shares were sold in multiple transactions, with prices ranging from $40.00 to $40.56. Phelps has committed to providing detailed information on the individual transaction prices upon request. For deeper insights into TEM's insider trading patterns and comprehensive financial analysis, investors can access additional InvestingPro metrics and expert tips. In other recent news, Tempus AI has been in the spotlight with significant developments. Following the company's recent earnings report, Piper Sandler increased the stock's price target from $40 to $70, maintaining a Neutral rating. Stifel downgraded Tempus AI's stock from Buy to Hold, yet raised the price target to $65, while Needham increased its price target to $56 and maintained a Buy rating. These adjustments followed Tempus AI's acquisition of Ambry Genetics, a strategic move that potentially introduces immediate genomics capabilities. Tempus AI also formed a strategic partnership with Avacta Therapeutics to use AI in advancing oncology drug development, providing Avacta access to Tempus's comprehensive multimodal datasets. In addition, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These are the latest developments for Tempus AI. The company's CEO, Eric Lefkofsky, has deferred the settlement of approximately 4.47 million restricted stock units to a period between January 15, 2025, and March 15, 2025. Tempus AI has also invested $36 million in Personalis (NASDAQ:PSNL), Inc., acquiring shares and exercising warrants for additional stock. These recent activities and strategic moves position Tempus AI for potential future growth, according to analyst firm Needham.

Tempus AI CFO James Rogers sells $59,057 in stock By Investing.com

CHICAGO -- James William Rogers (NYSE:ROG), Chief Financial Officer of Tempus AI, Inc. (NASDAQ:TEM), recently sold shares of the company's Class A common stock amid a challenging week for the company's stock, which has declined over 7%. According to a filing with the Securities and Exchange Commission, Rogers sold 1,468 shares on December 16, totaling approximately $59,057. The shares were sold at a weighted average price of $40.23, with transactions occurring at prices ranging from $40.00 to $40.56. Based on InvestingPro analysis, the stock is currently trading near its Fair Value. The transaction was a "sell to cover" sale, mandated by Tempus AI's equity incentive plans to fulfill statutory tax withholding obligations related to the vesting of restricted stock units. This sale was not a discretionary decision by Rogers. Following this transaction, Rogers retains ownership of 229,812 shares of Tempus AI. InvestingPro data shows the company maintains strong liquidity with a current ratio of 2.69, indicating healthy short-term financial stability. InvestingPro subscribers have access to 8 additional key insights about Tempus AI's financial position and market performance. In other recent news, Tempus AI's financial performance and strategic acquisitions have attracted significant attention from financial analysts. The company's recent earnings report led Piper Sandler to raise its price target from $40 to $70, while maintaining a neutral rating. Similarly, Stifel downgraded Tempus AI from Buy to Hold but increased the price target to $65, reflecting the recent acquisition of Ambry Genetics. Needham also raised its stock price target for Tempus AI to $56 following the company's third-quarter results and the Ambry Genetics acquisition. Meanwhile, Tempus AI has partnered with Avacta Therapeutics to utilize AI for oncology drug development. Another notable development includes FDA clearance for Tempus AI's Tempus ECG-AF device, which uses AI to identify patients at higher risk of atrial fibrillation/flutter. These recent developments have led to various financial firms adjusting their stock price targets for Tempus AI. While Piper Sandler and Stifel remain cautious with a Neutral and Hold rating respectively, Needham maintains its Buy rating, reflecting positive expectations for the company's growth trajectory. It is important to note that these ratings and targets are based on the company's recent financial performance and strategic moves, and not on the future stock price movements.